GET DAILY SIGNALSWhy Is Verastem Oncology (VSTM) Stock Down -15.14% Today?
Key Takeaways
- Shares fell 15.14% to approximately $7.96 from a prior close of $9.38, extending a post-earnings slide.
- Primary catalyst: a wider-than-expected third-quarter loss and a revenue miss reported after Thursday's close.
- Secondary driver: stalling commercialization of the AVMAPKI FAKZYNJA CO-PACK, with management guiding to a "more gradual sales ramp."
- Broader context: sharply higher R&D spending and a planned CEO transition added to investor caution.
- What traders watch next: the FDA decision on the blister-pack NDA (due by February 2027) and the year-end Phase 3 launch.
- For more detail on analyst expectations, explore Price Targets, Earnings, and Forecast pages for this ticker.
- For AI-driven trading ideas, explore Trending AI Robots.
Opening Summary
Verastem Oncology (VSTM), a Massachusetts-based biopharmaceutical company developing therapies for RAS/MAPK pathway-driven cancers, tumbled sharply in Friday's session. Shares dropped 15.14% to roughly $7.96, down from a prior closing price of $9.38. The selling was an earnings-driven move, as investors reacted to third-quarter results reported after Thursday's close that missed consensus on both the top and bottom lines and signaled a slowdown in the company's commercial launch.
Earnings Miss Triggers the Selloff
The immediate trigger for the decline was a disappointing third-quarter report. Verastem posted an adjusted loss of $0.72 per share, materially wider than the roughly $0.44-to-$0.47 per-share loss analysts had projected. Revenue came in at $24.01 million, below the consensus estimate of approximately $26 million to $28 million. While revenue more than doubled year over year and the GAAP loss narrowed, the market focused on the gap between results and expectations rather than the headline growth figures.
Commercial Ramp Stalls
A central concern weighing on the stock was the performance of AVMAPKI FAKZYNJA CO-PACK, the company's commercial product for KRAS-mutated recurrent low-grade serous ovarian cancer. Net product revenue slipped to $24.0 million from $25.1 million in the second quarter, breaking the sequential growth trend that had carried the launch forward. Management attributed the softness to seasonality, recent changes to the commercial team, and evolving off-label usage patterns, while cautioning that investors should anticipate a "more gradual sales ramp" going forward. That guidance reset near-term growth expectations and contributed to the negative market reaction.
Rising Costs and Leadership Transition
Investors also weighed a sharp increase in spending. Research and development expenses jumped roughly 137% year over year to $68.8 million as the company advanced its registration-directed clinical programs, pushing total operating expenses to approximately $99.2 million. Separately, the company confirmed a planned CEO transition, with Michael P. Bailey set to succeed Daniel Paterson effective January 1, 2027. While framed as part of an orderly succession plan, a leadership change during a pivotal commercialization and pipeline-building phase introduced an additional layer of uncertainty.
Market Context and Trading Activity
The move extended pressure that began in the after-hours and pre-market sessions following the earnings release, with trading activity running heavy relative to typical volumes as investors repositioned. The decline in VSTM reflected company-specific fundamentals rather than broad sector weakness, as the stock's sharp move diverged from a relatively stable backdrop in the broader biotechnology complex. The drop pushed shares well below recent trading levels in the $9.50-to-$10.10 range, undercutting short-term support and leaving the stock near its session lows.
What Comes Next for VSTM
The near-term focus for investors centers on the clinical and regulatory catalysts the company has teed up. Verastem plans to open its Phase 3 TARGET-D 301 trial in first-line KRAS G12D-driven metastatic pancreatic cancer by year-end, backed by encouraging early data for its VS-7375 candidate. An FDA decision on the blister-pack NDA is expected by February 7, 2027, and additional clinical data readouts are scheduled through 2027. Risks remain, including a crowded KRAS G12D competitive field, the potential for continued quarterly volatility in the commercial franchise, and elevated cash burn despite a $250 million October capital raise that extended the runway into the first half of 2028.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots designed to identify opportunities across thousands of tickers. While Tickeron offers hundreds of bots, only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a range of approaches to explore. Investors seeking a data-driven complement to their research may find the platform a useful resource.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for VSTM shows an upward move is likely
VSTM's Aroon Indicator triggered a bullish signal on October 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 188 similar instances where the Aroon Indicator showed a similar pattern. In 162 of the 188 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
VSTM moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 205 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
VSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 56 cases where VSTM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 77%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VSTM as a result. In 75 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for VSTM turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 36 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.237) is normal, around the industry mean (3.482). P/E Ratio (-3.447) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops drugs
Industry Biotechnology
Advertisement